Union Savings Bank Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Union Savings Bank bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,478 shares of the medical research company’s stock, valued at approximately $856,000.

Several other institutional investors have also bought and sold shares of the stock. Howard Capital Management Inc. lifted its stake in Thermo Fisher Scientific by 0.5% during the 4th quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company’s stock valued at $1,791,000 after acquiring an additional 16 shares in the last quarter. Petros Family Wealth LLC grew its stake in shares of Thermo Fisher Scientific by 3.9% in the 4th quarter. Petros Family Wealth LLC now owns 456 shares of the medical research company’s stock worth $264,000 after acquiring an additional 17 shares in the last quarter. Salomon & Ludwin LLC raised its holdings in shares of Thermo Fisher Scientific by 1.6% in the fourth quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company’s stock valued at $669,000 after purchasing an additional 17 shares during the last quarter. Pallas Capital Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 1.5% during the fourth quarter. Pallas Capital Advisors LLC now owns 1,256 shares of the medical research company’s stock valued at $728,000 after purchasing an additional 18 shares in the last quarter. Finally, Red Door Wealth Management LLC boosted its holdings in Thermo Fisher Scientific by 0.8% during the fourth quarter. Red Door Wealth Management LLC now owns 2,156 shares of the medical research company’s stock worth $1,250,000 after purchasing an additional 18 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on TMO. Barclays decreased their price objective on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Robert W. Baird dropped their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Royal Bank Of Canada set a $490.00 price objective on Thermo Fisher Scientific and gave the company a “sector perform” rating in a research note on Thursday, May 14th. Finally, Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $608.95.

Thermo Fisher Scientific Stock Up 0.3%

Thermo Fisher Scientific stock opened at $465.98 on Friday. The firm has a 50 day moving average price of $476.59 and a 200-day moving average price of $523.32. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $390.50 and a twelve month high of $643.99. The company has a market capitalization of $173.17 billion, a P/E ratio of 25.62, a P/E/G ratio of 2.06 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same quarter in the previous year, the firm posted $5.15 EPS. Thermo Fisher Scientific’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be paid a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.